BioNexus Gene Lab Corp. (BGLC)
NASDAQ: BGLC · Real-Time Price · USD
1.370
-0.140 (-9.27%)
Jul 27, 2026, 4:00 PM EDT - Market closed

BioNexus Gene Lab Financials Overview

Millions USD. Fiscal year is Jan - Dec.

Revenue & Profits

Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022
Period EndingMar '26 Dec '25 Dec '24 Dec '23 Dec '22
Revenue
5.317.429.519.7710.93
Revenue Growth
-42.69%-21.93%-2.66%-10.60%-
Gross Profit
0.741.091.291.331.26
Operating Income
-2.89-2.97-1.57-2.59-0.29
Net Income
-2.9-2.98-1.6-2.63-0.36
Earnings Per Share
-1.49-1.61-0.90-1.66-0.46
EPS Growth
-----

Revenue by Segment

Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingMar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Trading of Industrial Chemicals
5.297.419.499.7510.8311.85
Provision for Genomic Screening Services
0.020.020.020.020.11.52
Total
5.317.429.519.7710.9313.36

Cash & Debt

Fiscal YearCurrentFY 2025FY 2024FY 2023FY 2022
Period EndingMar '26 Dec '25 Dec '24 Dec '23 Dec '22
Cash & Investments
3.964.044.385.932.12
Total Debt
0.220.180.210.130.06
Net Cash (Debt)
3.753.864.175.82.06
Net Cash Growth
10.40%-7.28%-28.11%181.07%-
Net Cash Per Share
1.862.082.343.651.43

Cash Flow & CapEx

Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022
Period EndingMar '26 Dec '25 Dec '24 Dec '23 Dec '22
Operating Cash Flow
-1.16-1.84-2.09-1.820.55
Capital Expenditures
-0.03-0.04-0.23-0.15-0.05
Free Cash Flow
-1.19-1.88-2.32-1.970.5
Free Cash Flow Growth
-----

Margins

Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022
Period EndingMar '26 Dec '25 Dec '24 Dec '23 Dec '22
Gross Margin
13.95%14.62%13.56%13.61%11.52%
Operating Margin
-54.36%-39.93%-16.55%-26.54%-2.66%
Pretax Margin
-54.70%-40.20%-16.77%-26.69%-2.78%
Profit Margin
-54.70%-40.20%-16.81%-26.91%-3.26%
FCF Margin
-22.41%-25.26%-24.40%-20.18%4.55%

Valuation

Fiscal YearCurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingJul '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
PE Ratio
-----532.71
P/FCF Ratio
----331.62-
PS Ratio
0.641.290.530.9615.10-